Experienced in Synovial Sarcoma

Axel S. Merseburger

Ratzeburger Allee, 
Luebeck, SH, DE 
Experienced in Synovial Sarcoma
Ratzeburger Allee, 
Luebeck, SH, DE 
OverviewLocationsClinical Research

Overview

Axel Merseburger practices in Luebeck, Germany. Mr. Merseburger is rated as an Experienced expert by MediFind in the treatment of Synovial Sarcoma. His top areas of expertise are Prostate Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), Nephrectomy, and Lithotripsy.

His clinical research consists of co-authoring 445 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Synovial Sarcoma.

Gender
Male

Locations

Ratzeburger Allee, Luebeck, SH, Germany
Other Locations
Ratzeburger Allee 160, Luebeck, SH 23538, Germany
Ratzeburger Allee 160, Luebeck, SH 23562, Germany
Kuno Fischer Str. 8, Berlin, BE 14057, Germany
Carl Neuberg Str. 1, Hannover, NI 30625, Germany
Hoppe Seyler Str. 3, Tuebingen, BW 72076, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Real-world Evaluation of Efficacy and Safety With Avelumab (BAVENCIO®) + Axitinib (INLYTA®) in Patients With aRCC in Multiple EU Countries (AVION)
Real-world Evaluation of Efficacy and Safety With Avelumab (BAVENCIO®) + Axitinib (INLYTA®) in Patients With aRCC in Multiple EU Countries (AVION)
Enrollment Status: Completed
Publish Date: June 26, 2025
A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS)
A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS)
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
View 1 Less Clinical Trial

445 Total Publications

CONTACT-02: limited clinical benefit and a suboptimal control group - Authors' reply.
CONTACT-02: limited clinical benefit and a suboptimal control group - Authors' reply.
Journal: The Lancet. Oncology
Published: August 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Merseburger's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile